Progress of programmed death ligand 2 in immunotherapy of solid tumors / 肿瘤研究与临床
Cancer Research and Clinic
;
(6): 641-644, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-912939
ABSTRACT
With the breakthrough of immune checkpoint blocking therapy in the clinical treatment of a variety of malignant solid tumors, tumor immunotherapy has opened a new era. However, clinical practice has proved that the response rate of this therapy is low. Seeking for the key factors limiting its response rate has become a research hotspot in this field. Programmed death ligand 2 (PD-L2) is the second important ligand binding to programmed death 1 (PD-1) after programmed death ligand 1 (PD-L1). The encoded protein can bind to PD-1 and then inhibit immune cells. This paper reviews the biological characteristics of PD-L2, its mechanism in immune regulation and its research progress in solid tumor immunotherapy to provide more theoretical support for solid tumor immunotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research and Clinic
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS